consolidates information on NRF2-regulated transcripts, proteins, and metabolites validated in clinical or translational contexts, with relevance for disease monitoring and pharmacological response assessment.
The biomarker panel includes canonical NRF2 target genes such as NQO1, HMOX1 (HO-1), GCLM, TXNRD1, and SOD2; antioxidant enzymes and redox regulators measurable in plasma; and metabolites associated with glutathione metabolism, NADPH balance, lipid peroxidation, and inflammatory signaling. Together, these markers provide a multidimensional signature of NRF2 pathway activity that can be applied to evaluate disease severity, therapeutic efficacy, and treatment response across cardiovascular, metabolic, pulmonary, and neurodegenerative disorders.
Based on these findings, BenBedPhar partners have outlined the design of a multiplex biochip platform for the simultaneous quantification of NRF2-related biomarkers in blood samples. This conceptual biochip integrates transcriptomic and proteomic targets into a miniaturized diagnostic tool compatible with clinical workflows, aiming to enable rapid, quantitative, and reproducible readouts of NRF2 activation in patient cohorts.
This activity contributes directly to BenBedPhar’s mission to translate molecular knowledge into clinically applicable technologies, supporting the development of standardized monitoring tools for NRF2-targeted therapies in NCDs and reinforcing the Action’s translational and technological objectives.
